{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:38:24Z","timestamp":1790401104053,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.rmr.2024.07.006","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T21:29:11Z","timestamp":1724707751000},"page":"e55-e74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S1","title":["De l\u2019asthme difficile \u00e0 traiter \u00e0 l\u2019asthme s\u00e9v\u00e8re\u00a0: palier 5"],"prefix":"10.1016","volume":"41","author":[{"given":"S.","family":"Lejeune","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bierme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Baravalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schweitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Giovannini-Chami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2024.07.006_bib0460","unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Updated 2022. n.d."},{"key":"10.1016\/j.rmr.2024.07.006_bib0465","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1183\/09031936.00104809","article-title":"Problematic severe asthma in children, not one problem but many: a GA2LEN initiative","volume":"36","author":"Hedlin","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2024.07.006_bib0470","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1398-9995.2008.01672.x","article-title":"Severe asthma in childhood: assessed in 10 year olds in a birth cohort study","volume":"63","author":"Lang","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2024.07.006_bib0475","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/13993003.00780-2015","article-title":"The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts","volume":"46","author":"Fleming","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2024.07.006_bib0480","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/ACI.0b013e3280895d0c","article-title":"Difficult to control asthma in children","volume":"7","author":"Fleming","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0485","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12916-016-0657-8","article-title":"The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: analyses of standalone and linked national databases","volume":"14","author":"Mukherjee","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.rmr.2024.07.006_bib0490","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.anai.2011.04.008","article-title":"Economic burden of impairment in children with severe or difficult-to-treat asthma","volume":"107","author":"Szefler","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0495","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2024.07.006_bib0500","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jaci.2010.11.015","article-title":"Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health\/National Heart, Lung, and Blood Institute Severe Asthma Research Program","volume":"127","author":"Fitzpatrick","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0505","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/cea.12939","article-title":"Clinical phenotypes in asthma during childhood","volume":"47","author":"Just","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmr.2024.07.006_bib0510","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/cea.12095","article-title":"Atopy phenotypes in the Childhood Asthma Prevention Study (CAPS) cohort and the relationship with allergic disease: clinical mechanisms in allergic disease","volume":"43","author":"Garden","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmr.2024.07.006_bib0515","doi-asserted-by":"crossref","first-page":"e102987","DOI":"10.1371\/journal.pone.0102987","article-title":"Statistical cluster analysis of the British Thoracic Society Severe refractory Asthma Registry: clinical outcomes and phenotype stability","volume":"9","author":"Newby","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.rmr.2024.07.006_bib0520","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jpeds.2013.11.037","article-title":"Childhood allergic asthma is not a single phenotype","volume":"164","author":"Just","year":"2014","journal-title":"J Pediatr"},{"key":"10.1016\/j.rmr.2024.07.006_bib0525","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jaci.2016.08.014","article-title":"Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life","volume":"139","author":"Posa","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0530","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.jaip.2020.12.027","article-title":"Factors associated with asthma severity in children: data from the French COBRAPed Cohort","volume":"9","author":"Lezmi","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.07.006_bib0535","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1183\/09031936.00123411","article-title":"Two novel, severe asthma phenotypes identified during childhood using a clustering approach","volume":"40","author":"Just","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2024.07.006_bib0540","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.reval.2019.12.004","article-title":"Les ph\u00e9notypes de l\u2019asthme chez l\u2019enfant et l\u2019adolescent","volume":"60","author":"Just","year":"2020","journal-title":"Rev Fr Allergol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0545","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJMoa1513737","article-title":"Patterns of growth and decline in lung function in persistent childhood asthma","volume":"374","author":"McGeachie","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.07.006_bib0550","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaip.2017.05.032","article-title":"Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: differences with age","volume":"6","author":"Teague","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.07.006_bib0555","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaci.2019.09.030","article-title":"Severe asthma during childhood and adolescence: a longitudinal study","volume":"145","author":"Ross","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0560","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1081-1206(10)62557-4","article-title":"Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT","volume":"85","author":"Bender","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0565","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/(SICI)1099-0496(200001)29:1<39::AID-PPUL7>3.0.CO;2-G","article-title":"Poor inhalation technique, even after inhalation instructions, in children with asthma","volume":"29","author":"Kamps","year":"2000","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0570","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/apa.13059","article-title":"Getting the basics right resolves most cases of uncontrolled and problematic asthma","volume":"104","author":"de Groot","year":"2015","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.rmr.2024.07.006_bib0575","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0929-693X(02)00084-2","article-title":"[Difficult asthma in children]","volume":"9","author":"Iliescu","year":"2002","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.rmr.2024.07.006_bib0580","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/adc.2008.152140","article-title":"The importance of nurse-led home visits in the assessment of children with problematic asthma","volume":"94","author":"Bracken","year":"2009","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.rmr.2024.07.006_bib0585","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/ppul.25342","article-title":"When adherence and inhalation technique matter: difficult-to-control pediatric asthma in low- to middle-income countries","volume":"56","author":"Rodriguez-Martinez","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0590","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/ppul.20847","article-title":"Socioeconomic factors and asthma control in children","volume":"43","author":"Cope","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0595","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/ACI.0000000000000195","article-title":"Difficult-to-control asthma: epidemiology and its link with environmental factors","volume":"15","author":"Sheehan","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0600","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","article-title":"Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations","volume":"195","author":"Denlinger","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2024.07.006_bib0605","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1586\/ers.11.34","article-title":"Asthma-related comorbidities","volume":"5","author":"Boulet","year":"2011","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.rmr.2024.07.006_bib0610","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.alit.2018.11.007","article-title":"Severe asthma in children: evaluation and management","volume":"68","author":"Haktanir Abul","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.rmr.2024.07.006_bib0615","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1513\/AnnalsATS.201708-637FR","article-title":"A practical approach to severe asthma in children","volume":"15","author":"Barsky","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.rmr.2024.07.006_bib0620","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jped.2019.10.011","article-title":"High-resolution CT pulmonary findings in children with severe asthma","volume":"97","author":"Silva","year":"2021","journal-title":"J Pediatr (Rio J)"},{"key":"10.1016\/j.rmr.2024.07.006_bib0625","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jaci.2006.12.657","article-title":"The use of imaging techniques for assessing severe childhood asthma","volume":"119","author":"de Blic","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0630","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.rmr.2020.09.010","article-title":"[Lung imaging in severe asthma]","volume":"38","author":"Debray","year":"2021","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2024.07.006_bib0635","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/thx.2010.156836","article-title":"Use of sputum eosinophil counts to guide management in children with severe asthma","volume":"67","author":"Fleming","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2024.07.006_bib0640","doi-asserted-by":"crossref","first-page":"00332-2021","DOI":"10.1183\/23120541.00332-2021","article-title":"Benefits and risks of bronchoalveolar lavage in severe asthma in children","volume":"7","author":"Ben Tkhayat","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.rmr.2024.07.006_bib0645","doi-asserted-by":"crossref","first-page":"80s","DOI":"10.1016\/S0929-693X(04)90005-X","article-title":"[Severe asthma in children: identification and investigation]","volume":"11","author":"Marchac","year":"2004","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.rmr.2024.07.006_bib0650","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1183\/09031936.00186508","article-title":"Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma","volume":"34","author":"Bossley","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2024.07.006_bib0655","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1164\/rccm.201607-1453OC","article-title":"Effects of age and disease severity on systemic corticosteroid responses in asthma","volume":"195","author":"Phipatanakul","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2024.07.006_bib0660","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jaci.2015.12.1347","article-title":"Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach","volume":"138","author":"Bossley","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0665","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/pai.12990","article-title":"Pediatric asthma: an unmet need for more effective, focused treatments","volume":"30","author":"Papadopoulos","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0670","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/all.13749","article-title":"EAACI Guidelines on Allergen Immunotherapy: house dust mite-driven allergic asthma","volume":"74","author":"Agache","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2024.07.006_bib0675","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/pai.12759","article-title":"Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: a systematic review","volume":"28","author":"Rodrigo","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0680","doi-asserted-by":"crossref","first-page":"1801824","DOI":"10.1183\/13993003.01824-2018","article-title":"Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients","volume":"53","author":"Vogelberg","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2024.07.006_bib0685","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12931-015-0175-9","article-title":"A randomised dose-ranging study of tiotropium Respimat\u00ae in children with symptomatic asthma despite inhaled corticosteroids","volume":"16","author":"Vogelberg","year":"2015","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2024.07.006_bib0690","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jaip.2018.04.032","article-title":"Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma","volume":"6","author":"Vogelberg","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.07.006_bib0695","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2017.01.014","article-title":"A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma","volume":"140","author":"Szefler","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0700","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.jaip.2019.03.019","article-title":"Tiotropium is efficacious in 6- to 17-year-olds with asthma, independent of T2 phenotype","volume":"7","author":"Szefler","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.07.006_bib0705","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.chest.2022.02.025","article-title":"Azithromycin for poorly controlled asthma in children: a randomized controlled trial","volume":"161","author":"Ghimire","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2024.07.006_bib0710","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jaip.2022.11.036","article-title":"Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis","volume":"11","author":"Zuberbier","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.07.006_bib0715","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1542\/peds.108.2.e36","article-title":"Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)","volume":"108","author":"Milgrom","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.rmr.2024.07.006_bib0720","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1542\/peds.110.5.e55","article-title":"Omalizumab improves asthma-related quality of life in children with allergic asthma","volume":"110","author":"Lemanske","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.rmr.2024.07.006_bib0725","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1542\/peds.113.4.e308","article-title":"Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody","volume":"113","author":"Silkoff","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.rmr.2024.07.006_bib0730","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"Lanier","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0735","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1185\/03007991003771338","article-title":"Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma","volume":"26","author":"Kulus","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rmr.2024.07.006_bib0740","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.07.006_bib0745","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0750","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2017.03.002","article-title":"Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience","volume":"139","author":"Chipps","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0755","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/pai.13007","article-title":"New perspectives of childhood asthma treatment with biologics","volume":"30","author":"Just","year":"2019","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0760","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.anai.2019.11.016","article-title":"Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma","volume":"124","author":"Busse","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0765","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/cea.13373","article-title":"Asthma with multiple allergic comorbidities is associated with complete response to omalizumab","volume":"49","author":"Ses\u00e9","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmr.2024.07.006_bib0770","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2147\/JAA.S265657","article-title":"Precision medicine for paediatric severe asthma: current status and future direction","volume":"14","author":"Ramphul","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.rmr.2024.07.006_bib0775","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1183\/09031936.00149812","article-title":"Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey","volume":"42","author":"Deschildre","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2024.07.006_bib0780","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1183\/09031936.00008115","article-title":"Real-life long-term omalizumab therapy in children with severe allergic asthma","volume":"46","author":"Deschildre","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2024.07.006_bib0785","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/pai.12405","article-title":"Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents","volume":"26","author":"Rodrigo","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0790","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/ppul.23845","article-title":"Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: a real-life study","volume":"52","author":"Pitrez","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0795","doi-asserted-by":"crossref","first-page":"1702523","DOI":"10.1183\/13993003.02523-2017","article-title":"Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study","volume":"51","author":"Humbert","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2024.07.006_bib0800","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/archdischild-2011-301570","article-title":"The oral corticosteroid-sparing effect of omalizumab in children with severe asthma","volume":"97","author":"Brodlie","year":"2012","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.rmr.2024.07.006_bib0805","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201701-0120OC","article-title":"Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma","volume":"196","author":"Esquivel","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2024.07.006_bib0810","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.reval.2017.05.002","article-title":"Recommandations de la Soci\u00e9t\u00e9 fran\u00e7aise d\u2019allergologie. Indications des actes allergologiques en h\u00f4pital de jour","volume":"57","author":"Barnig","year":"2017","journal-title":"Rev Fr Allergol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0815","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1081-1206(10)62175-8","article-title":"Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma","volume":"91","author":"Berger","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0820","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1185\/03007995.2010.539502","article-title":"Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma","volume":"27","author":"Milgrom","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rmr.2024.07.006_bib0825","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaci.2016.03.030","article-title":"Anaphylactic reactions associated with omalizumab administration: analysis of a case-control study","volume":"138","author":"Lieberman","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0830","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.rmr.2021.09.005","volume":"39","author":"Deschildre","year":"2022","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2024.07.006_bib0835","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/all.13678","article-title":"Omalizumab discontinuation in children with severe allergic asthma: an observational real-life study","volume":"74","author":"Deschildre","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2024.07.006_bib0840","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2019.08.005","article-title":"Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype","volume":"144","author":"Gupta","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0845","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/ppul.24508","article-title":"Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma","volume":"54","author":"Gupta","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0850","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0140-6736(22)01198-9","article-title":"Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"400","author":"Jackson","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2024.07.006_bib0855","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2024.07.006_bib0860","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2024.07.006_bib0865","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jaip.2019.03.008","article-title":"Biologics for severe asthma: treatment-specific effects are important in choosing a specific agent","volume":"7","author":"Krings","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.07.006_bib0870","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.jaip.2019.05.053","article-title":"Proportion of severe asthma patients eligible for mepolizumab therapy by age and age of onset of asthma","volume":"7","author":"Comberiati","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.07.006_bib0875","doi-asserted-by":"crossref","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2024.07.006_bib0880","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0885","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/bjd.19460","article-title":"Dupilumab provides favourable long-term safety and efficacy in children aged\u00a0\u2265\u00a06 to\u00a0<\u00a012 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study","volume":"184","author":"Cork","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0890","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.07.006_bib0895","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(23)00303-X","article-title":"Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study","volume":"12","author":"Bacharier","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmr.2024.07.006_bib0900","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.rmr.2024.07.006_bib0905","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.07.006_bib0455","doi-asserted-by":"crossref","first-page":"2200606","DOI":"10.1183\/13993003.00606-2022","article-title":"Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA)","volume":"61","author":"Khaleva","year":"2023","journal-title":"Eur Respir J"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842524002456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842524002456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T13:36:03Z","timestamp":1729172163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842524002456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":91,"alternative-id":["S0761842524002456"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2024.07.006","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De l\u2019asthme difficile \u00e0 traiter \u00e0 l\u2019asthme s\u00e9v\u00e8re\u00a0: palier 5","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2024.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SPLF. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}